The Allogeneic Adult Stem Cells Company Announcing Appointment of Dr. Lev Verkh

The allogeneic adult stem cells manufacturer, Stemedica Cell Technologies, Inc., (a leader in adult stem cell research as well as manufacturing), announced today the appointment of Lev Verkh, PhD as Chief Regulatory and Clinical Development Officer. Dr. Verkh will be responsible for managing all regulatory activities and clinical trials on behalf of this allogeneic adult stem cells manufacturing company. . “Dr. Verkh brings over twenty years of international regulatory and clinical trial experience to Stemedica,” said Dr. Nikolai Tankovich, Stemedica’s President & Chief Medical Officer. “We are confident that his contribution to our mission to bring innovative products to patients, following FDA guidelines, will be significant.”

Dr. Verkh’s clinical and regulatory experience includes working for Pfizer, Baxter Bio Sciences, the Alliance Pharmaceutical Corporation and the Alpha Therapeutic Corporation. He has directed national and multi-national Phase I, II, III and IV clinical trials in such areas as cardiology, oncology, peripheral artery disease, hematology, blood disorders and imaging methods. He is author or co-author of over 40 peer-reviewed publications. Through his efforts and the efforts of his teams, he has received FDA approval for several products that are currently on the market. “I am honored to be joining Stemedica’s management team,” said Dr. Verkh, “and am excited to work with the company’s leading-edge allogenic adult stem cells technology.”

In addition to directing Stemedica’s stem cell clinical trials within the United States, Dr. Verkh will be assisting foreign regulatory agencies to establish guidelines for this allogeneic adult stem cells manufacturing unit in medicine. He will also assist in organizing and supervising stem cell clinical trials outside the United States utilizing Stemedica technology.

“With the rapid advancement of clinical application and development of allogeneic adult stem cells technologies around the world, the addition of Dr. Verkh is essential to our long-term growth plan”, said Maynard Howe, PhD, Stemedica’s Chief Executive Officer. “Stemedica is working closely with government leaders, scientists and clinicians to establish and promote best scientific practices in the emerging field of stem cell research and therapy.” The allogenic adult stem cells manufacturing company is preparing to improve medical condition of every human being to the maximum level.

Stemedica Cell Technologies Inc. (www.stemedica.com) is a specialty biopharmaceutical company that is committed to the development and manufacturing of best-in-class allogenic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and human stem cell clinical trials. The company is currently developing regulatory pathways for stroke, cardiomyopathy, diabetic retinopathy and wound repair. Stemedica is headquartered in San Diego, California.

Company - Stemedica Cell Technologies, Inc.
Contact Person - Dave McGuigan
Address - 5375 Mira Sorrento Place, Suite 120
City - San Diego
State - CA
Zip - 92121
Country - United States
Phone - 858-658-0910
Fax - 858-658-0986
Email - dmcguigan@stemedica.com

This release was published on openPR.